Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levalbuterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lupin Atlantis Holdings to Acquire Accretive Established Products in Europe and Canada from Sanofi
Details : Through th acquisition, Lupin expand its portfolio of accretive established products in Europe and Canada, including Xopenex (levalbuterol HCl), a short-acting β₂ adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulm...
Brand Name : Xopenex
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 23, 2023
Lead Product(s) : Levalbuterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?